Table 4.
Estimates and 95% confidence intervals from linear mixed-effects models for memory measures
| Clinical test | WMSR Log | AVLT Delayed | Sum AVLT | Sum AVLT | ||||
| Mem I model | Recall model | 1–5 model | 1–7 model | |||||
| Estimatea | p | Estimate | p | Estimate | p | Estimate | p | |
| Cross-sectional | ||||||||
| Age at death (5 y) | –0.04 (–0.53, 0.44) | 0.86 | –0.13 (–0.33, 0.08) | 0.23 | –0.51 (–1.11, 0.10) | 0.10 | –0.81 (–1.78, 0.16) | 0.10 |
| Male versus female | 0.03 (–1.38, 1.45) | 0.96 | –1.45 (–2.06, –0.85) | < 0.001 | –4.74 (–6.53, –2.95) | < 0.001 | –7.32 (–10.2, –4.47) | < 0.001 |
| APOE ɛ4 + versus ɛ4- | –0.82 (–2.41, 0.77) | 0.31 | –0.41 (–1.09, 0.28) | 0.24 | –0.47 (–2.49, 1.55) | 0.65 | –1.08 (–4.29, 2.14) | 0.51 |
| Aβ stage (1 level)b | –0.43 (–1.29, 0.44) | 0.33 | –0.16 (–0.54, 0.21) | 0.38 | –0.26 (–1.36, 0.84) | 0.64 | –0.63 (–2.38, 1.11) | 0.48 |
| Braak NFT stage (1 level) | –2.41 (–3.07, –1.75) | < 0.001 | –0.88 (–1.16, –0.59) | < 0.001 | –2.82 (–3.66, –1.98) | < 0.001 | –4.54 (–5.88, –3.20) | < 0.001 |
| LBD stage (1 level) | –0.15 (–0.82, 0.51) | 0.65 | –0.17 (–0.46, 0.11) | 0.23 | –0.26 (–1.10, 0.59) | 0.55 | –0.64 (–1.97, 0.70) | 0.35 |
| TDP-43 stage (1 level) | –1.86 (–2.72, –1.01) | < 0.001 | –0.87 (–1.24, –0.51) | < 0.001 | –2.31 (–3.39, –1.23) | < 0.001 | –3.85 (–5.57, –2.13) | < 0.001 |
| Longitudinal | ||||||||
| Time to death (1 y) | 0.21 (–0.15, 0.57) | 0.25 | 0.07 (–0.08, 0.23) | 0.36 | 0.26 (–0.18, 0.70) | 0.25 | 0.37 (–0.33, 1.06) | 0.30 |
| Age at death (5 y) | 0.04 (–0.04, 0.12) | 0.34 | 0.02 (–0.01, 0.06) | 0.25 | 0.16 (0.06, 0.25) | 0.001 | 0.23 (0.08, 0.39) | 0.003 |
| Male versus female | 0.11 (–0.11, 0.34) | 0.31 | 0.03 (–0.06, 0.13) | 0.49 | 0.08 (–0.19, 0.35) | 0.55 | 0.19 (–0.24, 0.63) | 0.38 |
| APOE ɛ4 + versus ɛ4- | –0.11 (–0.37, 0.15) | 0.40 | –0.03 (–0.14, 0.08) | 0.63 | –0.07 (–0.37, 0.24) | 0.67 | –0.16 (–0.65, 0.33) | 0.53 |
| Aβ stage (1 level) | 0.05 (–0.09, 0.19) | 0.45 | –0.03 (–0.09, 0.03) | 0.34 | –0.04 (–0.21, 0.12) | 0.60 | –0.08 (–0.34, 0.19) | 0.57 |
| Braak NFT stage (1 level) | –0.27 (–0.38, –0.15) | < 0.001 | –0.07 (–0.12, –0.02) | 0.007 | –0.32 (–0.45, –0.18) | < 0.001 | –0.49 (–0.70, –0.28) | < 0.001 |
| LBD stage (1 level) | 0.03 (–0.07, 0.13) | 0.53 | –0.02 (–0.06, 0.03) | 0.39 | –0.03 (–0.16, 0.09) | 0.60 | –0.06 (–0.26, 0.14) | 0.55 |
| TDP-43 stage (1 level) | –0.13 (–0.26, 0.00) | 0.054 | –0.02 (–0.07, 0.04) | 0.56 | –0.16 (–0.31, –0.0005) | 0.049 | –0.21 (–0.46, 0.04) | 0.10 |
aEstimates are expressed in terms of 1 point clinical score change. bAmyloid-β neuritic plaque score, CERAD C0-3.